News Portfolio - Page 2 of 5

Life Sciences 14. May 2024

Avelo collaborates with global health leaders in project “BreathForDiagnosis”

The €3 million research project is funded by the European Commission under "Horizon Europe", and co-funded by the Swiss State Secretariat for Education, Research and Innovation (SERI).

Life Sciences 25. March 2024

Follow-on investment in hemotune

Successful closing of the CHF 14 million Series B2 of hemotune under the lead of Belmondo and with the participation of OCCIDENT, as well as existing and new investors.

Life Sciences 20. March 2024

Resistell is publishing in Nature!

A peer-reviewed article on Resistell's rapid phenotypic solution for antibiotic susceptibility testing (AST) has been published in Nature Communications.

Life Sciences 14. March 2024

Follow-on investment in Tubulis

OCCIDENT is excited to announce its participation in Tubulis' €128 million Series B2 round co-led by EQT Life Sciences and Nextech Invest.

Life Sciences 20. February 2024

Initial Investment in Altavo

OCCIDENT is taking the lead in the oversubscribed €5 million Series A round of this Dresden-based MedTech start-up.

Life Sciences 14. December 2023

Avelo receives a 1.5M Innosuisse Grant

Following the Eurostars grant in October, our portfolio company Avelo, a Swiss breath diagnostics start-up, has been awarded the next grant.

Life Sciences 17. November 2023

Tubulis out-licenses TUB-010

Tubulis has inked its second major deal this year! As part of the deal, Tubulis out-licenses the Antibody-Drug Conjugate TEQ102 to Oncoteq.

Life Sciences 26. October 2023

Avelo wins €1.5 million Eurostars Grant

Avelo is now part of a consortium of three companies, including VIVOLTA from the Netherlands and BLINK from Germany.

Life Sciences 15. September 2023

Successful Exit adivo

We are excited to announce the successful exit of our portfolio company adivo, which we have supported from the very beginning as one of the first investors.